SEC Form 4 · accession 0001144204-15-027662
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philip Macneill
Officer — CFO
Period of report
May 1, 2015
Accepted (ET)
May 5, 2015 · 4:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF1 | May 1, 2015 | A | 25,000 | — | A | 25,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a grant of shares of restricted stock vesting on 05/01/2017 or earlier in certain circumstances. On the date of grant, the closing price of the Issuer's common stock on the NYSE MKT was $1.59 per share.